Literature DB >> 9174203

Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.

F J Boswell1, J M Andrews, R Wise.   

Abstract

Time-kill kinetics of BAY 12-8039 were studied at two inocula against three strains each of Bacteroides fragilis, Escherichia coli, Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pyogenes. The postantibiotic effects of BAY 12-8039 were studied on three strains each of E. coli, S. aureus, H. influenzae, Streptococcus pyogenes, and Streptococcus pneumoniae. The pharmacodynamic data demonstrated that BAY 12-8039 has marked activity against gram-positive and gram-negative organisms (under both anaerobic and aerobic conditions) and anaerobes. BAY 12-8039 also exhibited a postantibiotic effect of >1 h for all strains except one E. coli strain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174203      PMCID: PMC163919          DOI: 10.1128/AAC.41.6.1377

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.

Authors:  M A Cooper; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1991-09       Impact factor: 5.790

2.  The killing action of fleroxacin upon Bacteroides fragilis.

Authors:  D J Griggs; L J Piddock; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

3.  The bactericidal activity of sparfloxacin.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  J Antimicrob Chemother       Date:  1992-11       Impact factor: 5.790

4.  Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.

Authors:  R A Zabinski; K J Walker; A J Larsson; J A Moody; G W Kaatz; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

5.  In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.

Authors:  J M Hyatt; D E Nix; C W Stratton; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  5 in total
  10 in total

1.  In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.

Authors:  K Hamamoto; T Shimizu; N Fujimoto; Y Zhang; S Arai
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.

Authors:  E Miyazaki; M Miyazaki; J M Chen; R E Chaisson; W R Bishai
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell model.

Authors:  Delphine Paillard; Jean Grellet; Véronique Dubois; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 4.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Moxifloxacin.

Authors:  J A Balfour; L R Wiseman
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

6.  Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors.

Authors:  Stéphane Bronner; François Jehl; Jean-Daniel Peter; Marie-Cécile Ploy; Corinne Renault; Pierre Arvis; Henri Monteil; Gilles Prevost
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 7.  Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.

Authors:  J A Balfour; H M Lamb
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

8.  Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.

Authors:  V Rodriguez-Cerrato; C C McCoig; I C Michelow; F Ghaffar; H S Jafri; R D Hardy; C Patel; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 9.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.